Tumor-Derived HMGB1 Orchestrates Lysosomal Metabolic Reprogramming for M1 Macrophage Polarization.

Authors

Guoyu Zhang, Yi Cao, Xingxin Wu, Hanfang Liu, Min Zeng, Xiuzhong Sun, Song Huang, Jing Liang, Gaofei Li, Huimin Shen, Peng George Wang, Chaojie Wang, Dong Fang, Jiajia Wang, Songqiang Xie, Jing Ma

Published in

Journal of medicinal chemistry. Volume 69. Issue 16. Pages 20050-20064. Aug 27, 2026.

Abstract

Non-small-cell lung cancer (NSCLC) is considered as a predominant contributor to cancer-related mortality with significant infiltration by TAMs. HMGB1 plays a key role in modulating immune evasion, but the mechanisms of HMGB1 in anti-NSCLC immunotherapy remain unclear. In this study, we first identified that cisplatin-resistant A549 CisR overexpresses HMGB1 and has hyperactivated autophagy, while cisplatin-sensitive A549 cells exhibit the opposite reaction. Using a HMGB1-targeted modulator, Naphplatin, we show that normalizing HMGB1 in both A549 and A549 CisR cell lines significantly triggers HMGB1-mediated inherent metabolic plasticity in tumors, thus releasing it to the thresholds required for macrophage activation. Mechanistically, in tumors, HMGB1 at threshold levels can effectively translocate to the cytoplasm from the nucleus, initiating lysosomal metabolism. Meanwhile, in macrophages, tumor-derived HMGB1 binds to RAGE, thereby promoting polarization toward the M1 macrophage phenotype. This study uncovers a divergent metabolic program mediated by HMGB1 and demonstrates its role in lysosomal metabolic plasticity.

PMID:
42679161
Bibliographic data and abstract were imported from PubMed on 02 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.